These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
260 related articles for article (PubMed ID: 24532805)
1. G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia. Lee HK; Kim HW; Lee IY; Lee J; Lee J; Jung DS; Lee SY; Park SH; Hwang H; Choi JS; Kim JH; Kim SW; Kim JK; Cools J; Koh JS; Song HJ Blood; 2014 Apr; 123(14):2209-19. PubMed ID: 24532805 [TBL] [Abstract][Full Text] [Related]
2. A dual inhibitor overcomes drug-resistant FLT3-ITD acute myeloid leukemia. Wang P; Xiao X; Zhang Y; Zhang B; Li D; Liu M; Xie X; Liu C; Liu P; Ren R J Hematol Oncol; 2021 Jul; 14(1):105. PubMed ID: 34217323 [TBL] [Abstract][Full Text] [Related]
3. LT-171-861, a novel FLT3 inhibitor, shows excellent preclinical efficacy for the treatment of FLT3 mutant acute myeloid leukemia. Yu Z; Du J; Hui H; Kan S; Huo T; Zhao K; Wu T; Guo Q; Lu N Theranostics; 2021; 11(1):93-106. PubMed ID: 33391463 [No Abstract] [Full Text] [Related]
4. MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia. Xu B; Zhao Y; Wang X; Gong P; Ge W Leukemia; 2017 Apr; 31(4):913-921. PubMed ID: 27773927 [TBL] [Abstract][Full Text] [Related]
5. Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia. Park IK; Mundy-Bosse B; Whitman SP; Zhang X; Warner SL; Bearss DJ; Blum W; Marcucci G; Caligiuri MA Leukemia; 2015 Dec; 29(12):2382-9. PubMed ID: 26172401 [TBL] [Abstract][Full Text] [Related]
6. Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns. Moore AS; Faisal A; Gonzalez de Castro D; Bavetsias V; Sun C; Atrash B; Valenti M; de Haven Brandon A; Avery S; Mair D; Mirabella F; Swansbury J; Pearson AD; Workman P; Blagg J; Raynaud FI; Eccles SA; Linardopoulos S Leukemia; 2012 Jul; 26(7):1462-70. PubMed ID: 22354205 [TBL] [Abstract][Full Text] [Related]
7. Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML. Jeon JY; Zhao Q; Buelow DR; Phelps M; Walker AR; Mims AS; Vasu S; Behbehani G; Blachly J; Blum W; Klisovic RB; Byrd JC; Garzon R; Baker SD; Bhatnagar B Invest New Drugs; 2020 Apr; 38(2):340-349. PubMed ID: 31102119 [TBL] [Abstract][Full Text] [Related]
8. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies. Zhang W; Gao C; Konopleva M; Chen Y; Jacamo RO; Borthakur G; Cortes JE; Ravandi F; Ramachandran A; Andreeff M Clin Cancer Res; 2014 May; 20(9):2363-74. PubMed ID: 24619500 [TBL] [Abstract][Full Text] [Related]
9. Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation. Fathi AT; Blonquist TM; Hernandez D; Amrein PC; Ballen KK; McMasters M; Avigan DE; Joyce R; Logan EK; Hobbs G; Brunner AM; Joseph C; Perry AM; Burke M; Behnan T; Foster J; Bergeron MK; Moran JA; Ramos AY; Som TT; Rae J; Fishman KM; McGregor KL; Connolly C; Neuberg DS; Levis MJ Cancer; 2018 Jan; 124(2):306-314. PubMed ID: 28960265 [TBL] [Abstract][Full Text] [Related]
10. A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with Yamaura T; Nakatani T; Uda K; Ogura H; Shin W; Kurokawa N; Saito K; Fujikawa N; Date T; Takasaki M; Terada D; Hirai A; Akashi A; Chen F; Adachi Y; Ishikawa Y; Hayakawa F; Hagiwara S; Naoe T; Kiyoi H Blood; 2018 Jan; 131(4):426-438. PubMed ID: 29187377 [TBL] [Abstract][Full Text] [Related]
11. Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia. Baker SD; Zimmerman EI; Wang YD; Orwick S; Zatechka DS; Buaboonnam J; Neale GA; Olsen SR; Enemark EJ; Shurtleff S; Rubnitz JE; Mullighan CG; Inaba H Clin Cancer Res; 2013 Oct; 19(20):5758-68. PubMed ID: 23969938 [TBL] [Abstract][Full Text] [Related]
12. Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia. Zimmerman EI; Turner DC; Buaboonnam J; Hu S; Orwick S; Roberts MS; Janke LJ; Ramachandran A; Stewart CF; Inaba H; Baker SD Blood; 2013 Nov; 122(22):3607-15. PubMed ID: 24046014 [TBL] [Abstract][Full Text] [Related]
13. Expression of myeloid Src-family kinases is associated with poor prognosis in AML and influences Flt3-ITD kinase inhibitor acquired resistance. Patel RK; Weir MC; Shen K; Snyder D; Cooper VS; Smithgall TE PLoS One; 2019; 14(12):e0225887. PubMed ID: 31790499 [TBL] [Abstract][Full Text] [Related]
14. CCT245718, a dual FLT3/Aurora A inhibitor overcomes D835Y-mediated resistance to FLT3 inhibitors in acute myeloid leukaemia cells. Tariq MU; Furqan M; Parveen H; Ullah R; Muddassar M; Saleem RSZ; Bavetsias V; Linardopoulos S; Faisal A Br J Cancer; 2021 Sep; 125(7):966-974. PubMed ID: 34446858 [TBL] [Abstract][Full Text] [Related]
15. Discovery and development of extreme selective inhibitors of the ITD and D835Y mutant FLT3 kinases. Baska F; Sipos A; Őrfi Z; Nemes Z; Dobos J; Szántai-Kis C; Szabó E; Szénási G; Dézsi L; Hamar P; Cserepes MT; Tóvári J; Garamvölgyi R; Krekó M; Őrfi L Eur J Med Chem; 2019 Dec; 184():111710. PubMed ID: 31614258 [TBL] [Abstract][Full Text] [Related]
16. LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML. Beeharry N; Landrette S; Gayle S; Hernandez M; Grotzke JE; Young PR; Beckett P; Zhang X; Carter BZ; Andreeff M; Halene S; Xu T; Rothberg J; Lichenstein H Blood Adv; 2019 Nov; 3(22):3661-3673. PubMed ID: 31751472 [TBL] [Abstract][Full Text] [Related]
17. Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia. Mori M; Kaneko N; Ueno Y; Yamada M; Tanaka R; Saito R; Shimada I; Mori K; Kuromitsu S Invest New Drugs; 2017 Oct; 35(5):556-565. PubMed ID: 28516360 [TBL] [Abstract][Full Text] [Related]
18. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792 [TBL] [Abstract][Full Text] [Related]
19. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. Smith CC; Lasater EA; Zhu X; Lin KC; Stewart WK; Damon LE; Salerno S; Shah NP Blood; 2013 Apr; 121(16):3165-71. PubMed ID: 23430109 [TBL] [Abstract][Full Text] [Related]
20. FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia. Long J; Jia MY; Fang WY; Chen XJ; Mu LL; Wang ZY; Shen Y; Xiang RF; Wang LN; Wang L; Jiang CH; Jiang JL; Zhang WJ; Sun YD; Chang L; Gao WH; Wang Y; Li JM; Hong DL; Liang AB; Hu J Blood; 2020 Apr; 135(17):1472-1483. PubMed ID: 32315388 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]